Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Hold" by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have been assigned a consensus rating of "Hold" from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $61.90.

A number of equities research analysts have recently issued reports on HALO shares. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Finally, Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $53.73, for a total transaction of $1,074,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $39,422,721.87. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,497 shares of company stock worth $2,405,284. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Wealth Preservation Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $33,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 207 shares in the last quarter. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Finally, Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 0.4%

NASDAQ:HALO traded up $0.22 on Monday, hitting $54.22. 1,752,741 shares of the company's stock were exchanged, compared to its average volume of 1,756,220. The firm has a 50-day moving average price of $55.36 and a 200-day moving average price of $56.75. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. Halozyme Therapeutics has a 52 week low of $42.01 and a 52 week high of $70.51. The company has a market cap of $6.68 billion, a P/E ratio of 14.42, a price-to-earnings-growth ratio of 0.36 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The firm had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same period in the previous year, the firm posted $0.79 EPS. The company's revenue for the quarter was up 35.2% on a year-over-year basis. As a group, analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.